Analysen von Nicolas Guyon-Gellin
| 18.01.17 | AstraZeneca overweight | Morgan Stanley | |
| 02.11.16 | AstraZeneca overweight | Morgan Stanley | |
| 19.08.16 | AstraZeneca overweight | Morgan Stanley | |
| 13.07.16 | Novo Nordisk overweight | Morgan Stanley | |
| 09.06.16 | Novo Nordisk overweight | Morgan Stanley | |
| 22.04.16 | Novo Nordisk overweight | Morgan Stanley | |
| 22.03.16 | Novo Nordisk overweight | Morgan Stanley | |
| 09.03.16 | AstraZeneca overweight | Morgan Stanley | |
|
Werbung
|
|||
| 07.03.16 | Novo Nordisk overweight | Morgan Stanley | |
| 01.02.16 | Novo Nordisk overweight | Morgan Stanley | |
| 06.01.16 | Novo Nordisk overweight | Morgan Stanley | |
| 18.12.15 | AstraZeneca overweight | Morgan Stanley | |
| 03.12.15 | AstraZeneca overweight | Morgan Stanley | |
| 03.12.15 | AstraZeneca overweight | Morgan Stanley | |
| 05.05.15 | GSK overweight | Morgan Stanley | |
| 18.03.15 | GSK overweight | Morgan Stanley | |
| 23.10.14 | GSK overweight | Morgan Stanley | |
| 15.05.14 | GSK overweight | Morgan Stanley | |
| 21.12.12 | H. Lundbeck A-S kaufen | Exane-BNP Paribas SA | |
| 19.12.12 | Actelion outperform | Exane-BNP Paribas SA | |
| 19.12.12 | Shire outperform | Exane-BNP Paribas SA | |
| 20.11.12 | Novartis outperform | Exane-BNP Paribas SA | |
| 26.10.12 | Shire outperform | Exane-BNP Paribas SA | |
| 17.10.12 | Roche outperform | Exane-BNP Paribas SA | |